NVCR NovoCure: Enterprise Value-to-Revenue Multiple

NovoCure (NVCR) - corporate logo

The rise in share prices accompanied the implementation of TTFields for lung cancer and the expansion of NovoCure Limited (NVCR). The business valuation via EV/Sales reached a peak, after which the current level equals 1389.32. Monopoly status is ensured by exclusive patents for Tumor Treating Fields therapy. FDA approval and insurance reimbursements create a high barrier to entry, which protects the market position of NovoCure Limited (NVCR).

NVCR: NovoCure Limited EV/Sales Multiple 11/23/2025 - 11/20/2026

NVCR (NovoCure Corp): analytical breakdowns and indicator data

- current price and projected stock value:
- company stock capitalization data:
Initial company analysis:NVCR, NovoCure Limited
Core merchandise of NovoCure Ltd

The EV/Sales metric assesses the total enterprise value relative to revenue, excluding the impact of debt load to determine the asset's actual market price. For NovoCure Limited (NVCR), this calculation is critical during the implementation of TTFields therapy for lung cancer treatment. By analyzing the EV/Sales trend, an investor gains an objective view of scaling dynamics devoid of market speculation. Stability or growth in this ratio confirms the fundamental value of the expansion, verifying the company's resilience within the oncology sector.